PlatinumRx

PlatinumRx

Download App

Login
Diabetes Care
Type 2 Diabetes
Diabetes Medicines
Dietary Care
Insulin Injection
Test Strips
Sugar Substitutes
Health Conditions
Heart Care
Pain Relief
Digestive Care
Eye Care
Kidney Care
Liver Care
Respiratory Care
Stomach Care
Healthcare Devices
Miscellaneous
Personal Care
Skin Care
Sexual Wellness
Cough And Cold
Hair Care
Bone And Joint
Baby And Mom Care
Skin And Body Soap
Miscellaneous
Vitamins And Supplements
Calcium And Minerals
Vitamin A To Z
Minerals Supplements
Gut Health And Digestive Support
Vitamin B12 And Complex
Protein Supplements
Omega And Fish Oil
Baby And Mom Care
Vitamins And Bone Health Supplements
Supplement Powder
Nutritional Support For Hair
Heart And Circulatory Wellness
Miscellaneous
Health Resources
All Salts
All Diseases
All Medicines
All Health Products
All Brands
Blogs

Eribulin Mesylate

Uses

Eribulin Mesylate Uses Eribulin Mesylate is used in the treatment of metastatic breast cancer. It is indicated for adults with breast cancer that has spread to other parts of the body and who have already received other anticancer medications after the cancer has metastasized.

How it Works

How Eribulin Mesylate works Eribulin Mesylate is an anticancer medication that interferes with microtubule structures, which are essential for cancer cell division and multiplication. This action disrupts the growth cycle of cancer cells, ultimately leading to their death.

Side Effects

Common side effects of Eribulin Mesylate include anemia (low red blood cell count), weakness, hair loss, nausea, constipation, decreased white blood cell count, fatigue, and peripheral neuropathy (tingling and numbness in the hands and feet).

Expert Advice

  • Eribulin Mesylate is used to treat breast cancer that has metastasized to other areas of the body.
  • It is administered via an injection into a vein (intravenously).
  • Possible side effects include dizziness and fatigue.
  • Avoid driving or engaging in activities that require concentration until you understand how this medication affects you.
  • Use a reliable contraceptive method to prevent pregnancy while taking this medicine and for three months after discontinuation.
  • Your doctor may conduct regular blood tests to monitor your blood cell counts and electrolyte levels during treatment.
  • Inform your doctor immediately if you experience any signs of infection, such as fever, sore throat, rash, or severe diarrhea while on this medication.
  • It may cause numbness, tingling, or pricking sensations in your hands and feet.
  • Notify your doctor if these symptoms are bothersome.

Other Combinations

Related Medications

Molecule
Salt Composition in both

Eribulin Mesylate 0.5mg

hero_image
Cyebulin 0.5mg Injection
Intas Pharmaceuticals Ltd.
Vial of 2 ml
MRP

₹15,500

hero_image
Ebunat 0.5mg Injection
Natco Pharma Ltd.
Vial of 2 ml

₹13,720

MRP ₹19,600

11% Savings
Molecule
Salt Composition in both

Eribulin Mesylate 0.5mg

hero_image
Teceris Injection
Mylan Pharmaceuticals Pvt. Ltd.
Vial of 2 ml
MRP

₹31,879

hero_image
Ebunat 0.5mg Injection
Natco Pharma Ltd.
Vial of 2 ml

₹13,720

MRP ₹19,600

57% Savings
Molecule
Salt Composition in both

Eribulin Mesylate 0.5mg

hero_image
Evaira Injection
Zydus Cadila
Vial of 2 ml
MRP

₹20,995

hero_image
Ebunat 0.5mg Injection
Natco Pharma Ltd.
Vial of 2 ml

₹13,720

MRP ₹19,600

35% Savings
Molecule
Salt Composition in both

Eribulin Mesylate 0.5mg

hero_image
Mitobulin Solution for Injection
Cipla Ltd.
Vial of 1 Solution
MRP

₹13,500

hero_image
Ebunat 0.5mg Injection
Natco Pharma Ltd.
Vial of 2 ml

₹13,720

MRP ₹19,600

49% Savings
Molecule
Salt Composition in both

Eribulin Mesylate 0.5mg

hero_image
Embremma Injection
Emcure Pharmaceuticals Ltd.
Vial of 2 ml
MRP

₹21,430

hero_image
Ebunat 0.5mg Injection
Natco Pharma Ltd.
Vial of 2 ml

₹13,720

MRP ₹19,600

36% Savings
Molecule
Salt Composition

Eribulin Mesylate 0.5mg

hero_image
Ebunat 0.5mg Injection
Natco Pharma Ltd.
Vial of 2 ml

₹13,720

30% OFF

MRP ₹19,600

Molecule
Salt Composition

Eribulin Mesylate 1mg

hero_image
Eribulin 1mg Injection
Hetero Healthcare Ltd.
Vial of 2 ml
MRP

₹19,500

Sorry, the substitute medicine is Currently Unavailable
Molecule
Salt Composition

Eribulin Mesylate 0.44mg

hero_image
Epbriv 0.44mg Injection
Hetero Healthcare Ltd.
Vial of 2 ml
MRP

₹22,000

Sorry, the substitute medicine is Currently Unavailable
Molecule
Salt Composition

Eribulin Mesylate 1mg

hero_image
Eribilin Injection
Emcure Pharmaceuticals Ltd.
Vial of 2 ml
MRP

₹19,500

Sorry, the substitute medicine is Currently Unavailable
Molecule
Salt Composition

Eribulin Mesylate 1mg

hero_image
Halaven 1mg Injection
Eisai Pharmaceuticals India Pvt. Ltd.
Vial of 2 ml
MRP

₹31,885

Sorry, the substitute medicine is Currently Unavailable

Frequently asked questions

Eribulin Mesylate is administered via injection into a vein over 2 to 5 minutes. The dosage is based on your body surface area, calculated from your weight and height, and may be adjusted according to blood test results. A saline flush is recommended post-injection to ensure full dosage delivery.
Eribulin Mesylate is typically administered on Days 1 and 8 of each 21-day cycle. Treatment duration varies per individual, determined by your doctor. Blood test results may lead to delays or dose adjustments.
Hair loss is a common side effect of Eribulin Mesylate. It may be reversible, but severity varies among individuals. Consult your doctor with any concerns about hair loss.
Serious side effects of Eribulin Mesylate include low white blood cell count (neutropenia), which can lead to severe infections, and peripheral neuropathy, characterized by numbness, tingling, or pain in hands or feet. It may also harm an unborn baby if administered to pregnant women.
Women of childbearing age should use effective contraception during treatment and for up to 3 months afterward, as Eribulin Mesylate can cause serious birth defects. It should only be used during pregnancy if absolutely necessary and after careful risk assessment.
Eribulin Mesylate should be diluted in up to 100 ml of sodium chloride 9 mg/ml (0.9%) solution, not in 5% dextrose. It must be administered under the supervision of a physician experienced in cancer chemotherapy.
Handle Eribulin Mesylate with care, avoiding contact with skin, eyes, mouth, and nose. Use gloves, goggles, and protective clothing. If contact occurs, wash the area with soap and water immediately. Pregnant staff should not handle this medication.
;